Retmarker now available in Europe

Article

Critical Health has announced that Retmarker, its software solution for decision support in the ophthalmology domain, attained the right to hold the CE 0197 branding, that classifies it as a Class IIa Medical Device at a European level.

Critical Health has announced that Retmarker, its software solution for decision support in the ophthalmology domain, attained the right to hold the CE 0197 branding, that classifies it as a Class IIa Medical Device at a European level. This certification enables the company to start commercializing this software tool, which allows for a detailed analysis, using non-invasive imaging methods, of several retinal pathologies.

Available in several versions, RetmarkerDR monitors the progression of diabetic retinopathy using advanced proprietary algorithms that help ophthalmologists detect and calculate the formation and disappearance rates of microaneurysms in the retina. This allows them to infer, with the help of this information, the evolution of a disease that is one of the fastest growing causes of preventable blindness in developed countries. RetmarkerC enables the detection of changes in the retina due to several pathologies. Finally RetmarkerAMD is a new solution in development that enables the computer-assisted marking of digital images of patients with AMD, the main cause of blindness in persons over 50, in developed countries.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.